Medication prescribing errors pertaining to cardiovascular/antidiabetic medications: A prescription audit in primary care

Fundamental and Clinical Pharmacology

Volumn 26, Issue 3, 2012, Pages 410-417

  Al Khaja, Khalid A J ^a   Sequeira, Reginald P ^a   Damanhori, Awatif H H ^b  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

^b Ministry of Health   (Bahrain)

Author keywords

Bahrain; Cardiovascular antidiabetic medications; Prescribing errors; Prescription audit; Primary care

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPRETERAX; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; IRBESARTAN; LISINOPRIL; METFORMIN; PERINDOPRIL; SALBUTAMOL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ADULT; AGED; ARTICLE; BAHRAIN; DIABETES MELLITUS; DIABETIC PATIENT; DRUG MEGADOSE; ELDERLY CARE; FEMALE; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICATION ERROR; POLYPHARMACY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIHYPERTENSIVE AGENTS; BAHRAIN; CARDIOVASCULAR AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ERRORS; PHYSICIANS; PRIMARY HEALTH CARE; RANDOM ALLOCATION; RETROSPECTIVE STUDIES;

EID: 84860255924     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00924.x     Document Type: Article

References (43)

1. Sandars J., Esmail A. The frequency and nature of medical error in primary care: understanding the diversity across studies. Fam. Pract. (2003) 20 231-236.
2. Dean B., Schachter M., Vincent C., Barber N. Prescribing errors in hospital inpatients: their incidence and clinical significance. Qual. Saf. Health Care (2002) 11 340-344.
3. Bates D.W., Cullen D.J., Laird N. et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA (1995) 274 29-34.
4. Gandhi T.K., Weingart S.N., Borus J. et al. Adverse drug events in ambulatory care. N. Eng. J. Med. (2003) 348 1556-1564.
5. Ernst F.S., Grizzle A.J. Drug - related morbidity and mortality: updating the cost of illness model. J. Am. Pharm. Assoc. (2001) 41 156-157.
6. Zavaleta-Bustos M., Castro-Pastrana L.I., Reyes-Hernandez I., Lopez-Luna M.A., Bermudez-Camps I.B. Prescription errors in primary care university unit: urgency of pharmaceutical care in Mexico. Braz. J. Pharm. Sci. (2008) 44 115-125.
7. Ferner R.E., Aronson J.K. Clarification of terminology in medication errors. Drug Saf. (2006) 29 1011-1022.
8. Dean B., Barber N., Schachter M. What is a prescribing error? Qual. Health Care (2000) 9 232-237.
9. Al Khaja K.A.J., Al-Ansari T.M., Sequeira R.P. An evaluation of prescribing errors in primary care in Bahrain. Int. J. Clin. Pharmacol. Ther. (2005) 43 294-301.
10. Al Khaja K.A.J., Sequeira R.P., Al-Ansari T.M., Damanhori A.H.H. Prescription writing skills of residents in a family practice residency programme in Bahrain. Postgrad. Med. J. (2008) 84 198-204.
11. Mancia G., Gassi G., Zanchetti A. A new onset diabetes and antihypertensive drugs. J. Hyperten. (2006) 24 3-10.
12. Opie L.H., Schall R. Old antihypertensives and new diabetes. J. Hypertens. (2004) 22 1453-1458.
13. World Health Organization/International Society of Hypertensiion (WHO/ISH). Guidelines for the management of mild hypertension. J. Hypertens. (1999) 17 151-183.
14. Salvetti A., Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J. Am. Soc. Nephrol. (2006) 17 S25-S29.
15. Mancia G., de Backer G., Dominiczak A. et al. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. (2007) 25 1105-1187.
16. Arici M., Erdem Y. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am. J. Kidney Dis. (2009) 53 332-345.
17. Mogensen C., Neldam S., Tikkanen I. et al. Randomized controlled trial of dual blockade of renin-angiotensin systemin patients with hypertension, micro-albuminurea and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminurea (CALM) study. BMJ (2000) 321 1440-1444.
18. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet (2003) 361 117-124.
19. McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-added trial. Lancet (2003) 362 767-777.
20. Krum H., Carson P., Farsang C. et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from VaL-HeFT. Eur. J. Heart Fail. (2004) 6 937-945.
21. Yousuf S., Teo K.K., Pogue J. et al. (ONTARGET Investigators) Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Eng. J. Med. (2008) 358 1547-1559.
22. On behalf of the Canadian Hypertension Education Program (CHEP). 2009 CHEP recommendations. An annual update. Can. Fam. Physician (2009) 55 697-700.
23. Kolasinka-Malkowska K., Filipiak K.J., Gwizdala A., Tykarski A. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications. Expert Rev. Cardiovasc. Ther. (2008) 6 759-771.
24. Handler J. Dihydropyridine/Nonhydropyridine calcium channel blocker combination therapy. J. Clin. Hypertens (2005) 7 50-53.
25. Sassen J.J., Carter B.L., Brown T.E., Elliot W.J., Black H.R. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension (1996) 28 109-114.
26. Karotsis A.K., Symeonidis A., Mastorantonakis S.E., Stergiou G.S., Home-Di-Plus Study Group. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. Clin. Exp. Hypertens. (2006) 28 655-662.
27. Grimm R.H. Jr, Grandits G.A., Prineas R.J. et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in antihypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension (1997) 29(1pt1) 8-14.
28. Wassertheil-Smoller S., Blaufox M.D., Oberman A. et al. Effect of antihypertensives on sexual function and quality of life: The TAIM study. Ann. Intern. Med. (1991) 114 613-620.
29. Anonymous. British National Formulary (BNF) No. 58. BMJ Group and RPS Publishing, London, 2009.
30. Sweetman S.C. Martindale. The Complete Drug Reference. Pharmaceutical Press, London, 2007.
31. 12 deficiency in patients receiving metformin. Arch. Int. Med. (2006) 166 1975-1978.
32. Metthews J.H. Cobalamin and folate deficiency in elderly. Baillieres Clin. Haematol. (1995) 8 679-697.
33. Lee F.T.H. Advances in diabetes in the elderly. J. Pharm. Pract. Res. (2009) 39 63-67.
34. Gregoria F., Ambrosi F., Fillipponi P., Manfrini S., Testa I. Is metformin safe enough for aging type 2 diabetic patients? Diabetes Metab. (1996) 22 43-50.
35. Groop L., Luzi L., Melander A. et al. Different effects of glibenclamide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes (1987) 36 1320-1328.
36. Cox A.R., Ferner R.E. Prescribing errors in diabetes. Br. J. Diabetes Vas. Dis. (2009) 9 84-88.
37. Al Khaja K.A.J., Sequeira R.P., Mathur V.S. Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain. Ann. Pharmacother. (2001) 35 1350-1359.
38. Al Khaja K.A.J., Sequeira R.P., Mathur V.S., Damanhori A.H.H., Abdul Wahab A.W. Family physicians; and general practitioners' approaches to drug management of diabetic hypertension in primary care. J. Eval. Clin. Pract. (2002) 8 19-30.
39. Papa G., Fedele V., Rizzo M.R. et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people. Diabetes Care (2006) 29 1918-1920.
40. Hornick T., Aron D.C. Managing diabetes in the elderly: go easy, individualize. Cleve. Clin. J. Med. (2008) 75 70-78.
41. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet (2006) 367 1665-1673.
42. Verro P., Gorelick P.B., Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke (2008) 39 1358-1363.
43. Bousser M.G., Eschwege E., Haguenayu M. et al. 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke (1983) 14 5-14.